Heart Failure Clinical Trial
MPO Inhibitor A_Zeneca for HFpEF
Summary
Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure versus placebo.
Full Description
Enroll subjects with a normal ejection fraction referred to the catheterization laboratory for evaluation of breathlessness or shortness of breath. Perform safety lab sampling, echocardiography, arterial tonometry for pulse wave analysis, and assessment of endothelial function prior to administration of study drug. During the catheterization researchers will perform blood draws, assess baseline exercise capacity at rest and during exercise. Researchers will also do an echocardiogram to take measurements of the heart. Subjects will be randomized to one of two groups, Oral Myeloperoxidase Inhibitor or placebo group. Study drug or placebo will be administered followed by a repeat of the baseline catheterization assessments. At the conclusion of the second exercise test the subject will be moved to a room and monitored overnight for safety. Repeat blood draws, echocardiogram, endothelial function test, and heart monitoring will be completed. The subject will be asked to follow up with the researchers between 9-14 days after the study drug dosage. The subjects history and blood work will be completed at that visit.
Eligibility Criteria
Inclusion Criteria:
Males and females of non-childbearing potential
Age ≥ 30 years
Symptoms of dyspnea (II-IV) at the time of screening
EF ≥ 50% as determined on imaging study within 12 months of enrollment
Catheterization documented elevated filling pressures at rest (PCWP ≥15) or with exercise (PCWP ≥25)
Exclusion Criteria:
Use of nitrates, phosphodiesterase 5 inhibitors or other NO-providing therapy in the past 24 hours of screening
Significant valvular disease (>moderate left-sided regurgitation, >mild stenosis)
Requirement of intravenous heparin at the start of case
Severe pulmonary parenchymal disease
Acute coronary syndrome or coronary disease requiring revascularization in the judgement of investigators
Resting systolic blood pressure < 100 mmHg
Constrictive pericarditis
Infiltrative, restrictive, or hypertrophic obstructive cardiomyopathies
Previous anaphylaxis to any drug
Pregnancy or breastfeeding mothers
High Output heart failure
Active thyroid disease
Treatment with a new chemical entity (defined as a compound which has not been approved for marketing) within the preceding 3 months
Patients with any prior allergy to propylthiouracil
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Rochester Minnesota, 55905, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.